LYSINE
Neuroendocrine Tumor of the Lung
David BushnellSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Neuroendocrine Tumor of the Lung cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Everolimus AC Camargo Cancer Center | Phase 2 | CCC |
177lu-dtpa-sc16.56 Memorial Sloan Kettering Cancer Center | Phase 1 | CC |
212-lead pentixather Yusuf Menda | Early Phase 1 | C |
ARG David Bushnell | Early Phase 1 | C |
[212pb] vmt-α-net David Bushnell | Early Phase 1 | C |
Same molecule, other indications
LYSINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →